CN102333788A - 因子viii的修饰 - Google Patents

因子viii的修饰 Download PDF

Info

Publication number
CN102333788A
CN102333788A CN2010800074950A CN201080007495A CN102333788A CN 102333788 A CN102333788 A CN 102333788A CN 2010800074950 A CN2010800074950 A CN 2010800074950A CN 201080007495 A CN201080007495 A CN 201080007495A CN 102333788 A CN102333788 A CN 102333788A
Authority
CN
China
Prior art keywords
factor viii
ethoxy
moiety
integer
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800074950A
Other languages
English (en)
Chinese (zh)
Inventor
M.赞德尔
B.佩施克
D.M.卡普夫
K.马德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN102333788A publication Critical patent/CN102333788A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2010800074950A 2009-02-19 2010-02-18 因子viii的修饰 Pending CN102333788A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09153257.2 2009-02-19
EP09153257 2009-02-19
US16151009P 2009-03-19 2009-03-19
US61/161510 2009-03-19
PCT/EP2010/052022 WO2010102886A1 (en) 2009-02-19 2010-02-18 Modification of factor viii

Publications (1)

Publication Number Publication Date
CN102333788A true CN102333788A (zh) 2012-01-25

Family

ID=40935766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800074950A Pending CN102333788A (zh) 2009-02-19 2010-02-18 因子viii的修饰

Country Status (6)

Country Link
US (1) US20110306551A1 (https=)
EP (1) EP2398822B1 (https=)
JP (1) JP2012518029A (https=)
CN (1) CN102333788A (https=)
ES (1) ES2401965T3 (https=)
WO (1) WO2010102886A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011798A1 (zh) * 2015-01-27 2016-01-28 深圳华大基因研究院 用于保存生物样品的稳定剂

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
ES2597954T3 (es) * 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
CA2821945A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
WO2013123409A1 (en) * 2012-02-17 2013-08-22 NVS Technologies, Inc. Polymer scaffolds for assay applications
US20160000884A1 (en) * 2012-08-13 2016-01-07 Novo Nordisk A/S Liquid Factor VIII Formulations
CA2914178C (en) 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3016975B1 (en) 2013-07-04 2019-01-16 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
AU2014286990A1 (en) 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
JP6513095B2 (ja) 2014-01-03 2019-05-15 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
PT3319939T (pt) 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Inibidores de desoxiuridina-trifosfatase contendo hidantoína
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
WO2019229242A1 (en) 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2022096636A1 (en) 2020-11-06 2022-05-12 Novo Nordisk A/S Glp-1 prodrugs and uses hereof
WO2023285334A1 (en) 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
AR129270A1 (es) 2022-05-10 2024-08-07 Novo Nordisk As Profármacos y usos de los mismos
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
CN120435491A (zh) 2022-12-22 2025-08-05 诺和诺德股份有限公司 胰淀素受体激动剂
KR20240163292A (ko) * 2023-05-10 2024-11-19 주식회사 아미노로직스 모노-터트-부틸 에스터화된 포화 탄화수소의 제조방법 및 이의 순환적 제조방법
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
JP7826558B1 (ja) 2024-10-11 2026-03-09 ノヴォ ノルディスク アー／エス ヒトｆｇｆ２３のアンタゴニスト

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268976A (zh) * 1997-05-16 2000-10-04 诺沃诺尔迪斯克生物技术有限公司 具有脯氨酰二肽氨肽酶活性的多肽和编码该多肽的核酸
CN1767857A (zh) * 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 聚合物－因子ⅷ部分共轭物
CN1909930A (zh) * 2004-01-21 2007-02-07 诺和诺德公司 转谷氨酰胺酶介导的肽的接合
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
CN101124331A (zh) * 2004-11-12 2008-02-13 拜尔健康护理有限责任公司 Fⅷ的位点定向修饰

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665280B2 (ja) * 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DE69333718T2 (de) 1992-01-14 2005-12-01 Ajinomoto Co., Inc. Gen, das für eine Fisch-Transglutaminase kodiert
DK128193D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
US5736356A (en) 1994-01-28 1998-04-07 Ajinomoto Co., Inc. Transglutaminase originating from Crassostrea gigas
NZ291414A (en) 1994-08-26 1998-05-27 Novo Nordisk As Microbial transglutaminases and methods of production using fungi and dna constructs
CA2208730A1 (en) 1995-01-19 1996-07-25 Novo Nordisk A/S Transglutaminases from oomycetes
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268976A (zh) * 1997-05-16 2000-10-04 诺沃诺尔迪斯克生物技术有限公司 具有脯氨酰二肽氨肽酶活性的多肽和编码该多肽的核酸
CN1767857A (zh) * 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 聚合物－因子ⅷ部分共轭物
CN1909930A (zh) * 2004-01-21 2007-02-07 诺和诺德公司 转谷氨酰胺酶介导的肽的接合
CN101124331A (zh) * 2004-11-12 2008-02-13 拜尔健康护理有限责任公司 Fⅷ的位点定向修饰
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011798A1 (zh) * 2015-01-27 2016-01-28 深圳华大基因研究院 用于保存生物样品的稳定剂
CN105636937A (zh) * 2015-01-27 2016-06-01 深圳华大基因研究院 用于保存生物样品的稳定剂
CN105636937B (zh) * 2015-01-27 2018-07-17 深圳华大生命科学研究院 用于保存生物样品的稳定剂
US10494661B2 (en) 2015-01-27 2019-12-03 Bgi Shenzhen Stabilizer for preserving biological samples

Also Published As

Publication number Publication date
JP2012518029A (ja) 2012-08-09
EP2398822A1 (en) 2011-12-28
US20110306551A1 (en) 2011-12-15
ES2401965T3 (es) 2013-04-25
EP2398822B1 (en) 2013-01-02
WO2010102886A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CN102333788A (zh) 因子viii的修饰
JP5977945B2 (ja) 長期のインビボ有効性を有するコンジュゲートタンパク質
ES2434035T3 (es) Conjugados de polímero-factor von Willebrand
JP5702066B2 (ja) 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
CN102770449B (zh) 具有降低的vwf结合的因子viii分子
CN102639553A (zh) 纯化聚乙二醇化蛋白质的方法
JP5946822B2 (ja) タンパク質の選択的改変
CN101010333B (zh) 从生物材料中纯化凝血因子xⅲ多肽
JP2018529760A5 (https=)
JPH10509208A (ja) 部位特異的結合のための官能化されたポリマー
JP2008545644A (ja) 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法
HK1127300A (en) Pegylated factor viii
BRPI0720661B1 (pt) Conjugados do polímero-fator de von willebrand e polímero-do fator viii tendo uma ligação liberável, método e composição relacionados

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120125